Related Experiment Video

Updated: Sep 14, 2025

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.1K

The post-translational modification of NuMA in cancer cells is a new target for cancer eradication

Malka Cohen-Armon1

  • 1Faculty of Medical and Health Sciences, Gray School of Medicine and Sagol School of Neuroscience, Tel-Aviv University, Tel Aviv, Israel. marmon@tauex.tau.ac.il.

Cell Death & Disease
|July 18, 2025
PubMed

Insights

Researchers discovered a novel cancer cell death pathway by inhibiting nuclear mitotic apparatus protein (NuMA) modification. This targeted approach halts mitosis in cancer cells, leading to their eradication irrespective of mutations.

Area of Science:

  • Oncology
  • Cell Biology
  • Biochemistry

Background:

  • Nuclear mitotic apparatus protein (NuMA) is essential for mitosis in both healthy and malignant cells.
  • Cancer cells often exhibit uncontrolled proliferation due to dysregulated cell division processes.

Purpose of the Study:

  • To identify and characterize a novel cell-death mechanism specifically targeting human cancer cells.
  • To investigate the role of NuMA post-translational modification in cancer cell viability.

Main Methods:

  • Inhibition of NuMA post-translational modification in human cancer cell lines.
  • Analysis of mitotic spindle pole structure and function.
  • Assessment of mitosis progression and cell death induction.

Main Results:

  • Inhibition of NuMA modification leads to structural defects in mitotic spindle poles.
  • These defects cause mitosis arrest specifically in cancer cells.
  • Cancer cell death is triggered by mitosis arrest, independent of specific cancer mutations.

Conclusions:

  • A novel, mutation-independent cancer cell-death mechanism targeting NuMA has been identified.
  • This mechanism offers a promising strategy for eradicating diverse human cancers.
  • Targeting NuMA modification represents a potential therapeutic avenue in oncology.

More Related Videos

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

492
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
The Nucleolus02:55

The Nucleolus

The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
9.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K